Jun 13th 2012 - Edison Investment Research today published a report on EpiCept Corporation entitled "Moving Forward With Pain". In summary, the report says:
EpiCept’s investment case is centred on finding a development partner for AmiKet, a product for chemotherapy-induced peripheral neuropathy. Although EpiCept’s valuation is depressed as a result of the ongoing regulatory and commercial setbacks with respect to Ceplene and Azixa, the upside from a successful deal – which might include an M&A transaction – could be considerable. Cash currently lasts to Q3, while our valuation – presuming Amiket is partnered – is a multiple of the current share price.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »